Login / Signup

Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.

Hector Garcia-MorenoMercedes PrudencioGilbert Thomas-BlackNita SolankyKaren R Jansen-WestRana Hanna Al-ShaikhAmanda J HeslegraveHenrik ZetterbergMagda M SantanaLuis Pereira de AlmeidaAna Vasconcelos-FerreiraCristina JanuárioJon InfanteJennifer FaberThomas KlockgetherKathrin ReetzMafalda RaposoAna F FerreiraManuela LimaLudger SchölsMatthis SynofzikJeannette HübenerAndreas PuschmannSorina GorcencoZbigniew K WszolekLeonard PetrucelliPaola Giunti
Published in: European journal of neurology (2022)
Our results suggest that tau might be a marker of early disease stages in SCA3. NfL can discriminate mutation carriers from controls and is associated with different clinical variables. Longitudinal studies are required to confirm their potential role as biomarkers in clinical trials.
Keyphrases
  • cerebrospinal fluid
  • clinical trial
  • early onset
  • cross sectional
  • randomized controlled trial
  • case control
  • phase ii
  • open label
  • phase iii